Using S-adenosylmethionine to treat alcoholic cirrhosis
S-adenosylmethionine treatment in alcoholic cirrhosis
This study is looking at whether a supplement called SAMe can help improve liver health and reduce inflammation in people with alcoholic cirrhosis, a serious liver problem caused by drinking too much alcohol.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10689946 on NIH RePORTER |
What this research studies
This research investigates the potential of S-adenosylmethionine (SAMe) as a treatment for alcoholic cirrhosis, a serious liver condition caused by excessive alcohol consumption. The study aims to understand how SAMe can help restore liver function and reduce inflammation associated with the disease. Patients will be monitored for changes in liver health and overall well-being over the course of the treatment. The research involves collaboration between multiple academic centers and aims to build on previous findings regarding SAMe's effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with alcoholic cirrhosis who are seeking treatment options.
Not a fit: Patients who do not have alcoholic cirrhosis or those who are not willing to abstain from alcohol during the treatment period may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option that improves liver health and reduces mortality in patients with alcoholic cirrhosis.
How similar studies have performed: Previous studies have shown some promise for SAMe in treating liver conditions, but this specific approach in alcoholic cirrhosis is still being explored and has not been fully validated.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Liangpunsakul, Suthat — Indiana University Indianapolis
- Study coordinator: Liangpunsakul, Suthat
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.